Awani International
  • LIVE
  • Videos
  • US-China
  • BRICS-RT
  • ASEAN
  • West Asia
  • Shows
  • Podcast
  • BM
    EN
  • LIVE
  • Login
  • BM
    EN
  • LIVE
  • Login
Awani International
  • LIVE
  • Videos
  • US-China
  • BRICS-RT
  • ASEAN
  • West Asia
  • Shows
  • Podcast
The end of the European Union is nigh: Greenland proves it
Trump's Greenland threat puts Europe Inc back in tariff crosshairs
Europe won't be 'blackmailed' by Trump tariffs, says Danish PM
  • PRIVACY POLICY
  • TERMS OF USE
  • ADVERTISE WITH US
  • INVESTOR

Astro AWANI | Copyright © 2025 Measat Broadcast Network Systems Sdn Bhd 199201008561 (240064-A)

Malaysia approves Sinovac's COVID-19 vaccine for ages 12 to 17

Reuters
Reuters
01/10/2021
04:04 MYT
Malaysia approves Sinovac's COVID-19 vaccine for ages 12 to 17
Malaysia's drugs regulator advised priority for Sinovac's product among teenagers without comorbidities or allergy problems. - REUTERS photo
KUALA LUMPUR: Malaysia has given conditional approval for a COVID-19 vaccine made by China's Sinovac to be used on young people aged between 12 and 17, its health ministry said on Friday.
Teenagers younger than 18 began receiving COVID-19 doses last month, after vaccinations of more than 80% of adults were completed in one of Southeast Asia's fastest vaccine rollouts that has covered 62% of a population of 32 million.
In a statement, the health ministry said Malaysia's drugs regulator advised priority for Sinovac's product among teenagers without comorbidities or allergy problems, or otherwise deemed unsuitable for the Pfizer-BioNTech vaccine.
In July, Malaysia said it would stop giving the Sinovac shot when supplies ran out, as it had enough of other vaccines for the national campaign.
Malaysia has continued to receive additional shipments, however. This week, the foreign ministry said China had agreed to donate a million doses of the Sinovac vaccine, following a donation of 500,000 in July.
Related Topics
#Pfizer-BioNTech
#Malaysia
#Sinovac
#teenagers
#English News
Must-Watch Video
Stay updated with our news